News & Events – Ysios Capital

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

Swiss Biotech Day 2026
4 May - 5 May, 2026
Zurich
Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
20 -22 May, 2026
Malta
CFO Forum
21 - 22 May, 2026
Málaga
BIOSPAIN
29 September - 1 October, 2026
Bilbao

Type:

Year:

Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01<

Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01

The patient was dosed at The Memorial Sloan Kettering Cancer Center in New York.

SparingVision appoints Dr. Kali Stasi as Chief Medical Officer

Over 30 years of experience across academic research, biotech, and pharma

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)<

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Lorundrostat demonstrated a favorable safety and tolerability profile

ReproNovo raises $65 million Series A financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and women’s health<

ReproNovo raises $65 million Series A financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and women’s health

Ysios Capital joins Repronovo's $65M Series A financing

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights<

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

Seasoned leader whose extensive operational and commercial experience will be instrumental

Cytoki Pharma Highlights Data Reinforcing Therapeutic Potential of Lipidated IL22 for IBD in Digestive Diseases and Sciences Publication<

Cytoki Pharma Highlights Data Reinforcing Therapeutic Potential of Lipidated IL22 for IBD in Digestive Diseases and Sciences Publication

Findings support lipidated IL-22 as a differentiated treatment option to address the significant unmet need in IBD

CorWave Announces Successful Completion of 6-Month Chronic In Vivo Study, Paving the Way for Clinical Trial Initiation<

CorWave Announces Successful Completion of 6-Month Chronic In Vivo Study, Paving the Way for Clinical Trial Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer<

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer

Phase 1 clinical trial of TGW101 initiated; Company plans to enroll up to 50 patients with advanced solid tumors in the U.S

SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary to Dry-AMD<

SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary to Dry-AMD

Advancement of SPVN06 into a second indication is supported by robust clinical safety and preclinical data from the ongoing program in RP

Anaconda Biomed Announces Publication of ANAIS Study Results in the American Journal of Neuroradiology

Data support use of its ANA funnel catheter as an adjunct to stent retriever thrombectomy in the treatment of acute ischemic stroke

« Previous 1 … 6 7 8 9 10 … 77 Next »